Stockreport

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update [TheStreet.com]

NeuroSense Therapeutics Ltd. - Ordinary Shares  (NRSN) 
PDF March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatm [Read more]